Cabergoline has agonist activity on the D2 receptor of Dopamine, while inhibiting Prolactin secretion. Therefore, Cabergoline is indicated for the treatment of Parkinson's disease or hyperprolactinemia. So what principles should be followed when using Cabergoline?